The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
Glycogen phosphorylase inhibitors for treatment of type 2 diabetes mellitus
Abstract
Type 2 diabetes mellitus is a severe disease with large economic consequences, which is significantly under-diagnosed and incompletely treated in the general population. Control of blood glucose levels is a key objective in treating diabetic patients, who are most often prescribed one or more oral hypoglycaemic agents in addition to diet and exercise modification as well as insulin. In spite of the availability of different classes of hypoglycaemic drugs, treatment regimens are often unable to achieve an intensive degree of glucose control known to most effectively reduce the incidence and severity of diabetic complications. Hepatic glucose output is elevated in type 2 diabetic patients and current evidence indicates that glycogenolysis (release of monomeric glucose from the glycogen polymer storage form) is an important contributor to the abnormally high production of glucose by the liver. Glycogen phosphorylase is the enzyme that catalyses this release and recent advances in new inhibitors of this structurally and kinetically well studied enzyme have enabled work which further delineate the pharmacological and physiological consequences of inhibiting glucose production by this pathway. Most notably, these agents lower glucose in diabetic animal models, both acutely and chronically, appear to affect both gluconeogenic and glycogenolytic pathways and demonstrate potential for a beneficial effect on cardiovascular risk factors. Cumulatively, this information has bolstered interest and promise in glycogen phosphorylase inhibitors (GPIs) as potential new hypoglycaemic agents for treatment of type 2 diabetes mellitus.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Haffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807233390404 · Cited by 7,000
Global Burden of Diabetes, 1995–2025: Prevalence, numerical estimates, and projections
King, H., Aubert, R. E., & Herman, W. H. (1998) · Diabetes Care · doi:10.2337/diacare.21.9.1414 · Cited by 6,311
Harris, M. I., Flegal, K. M., Cowie, C. C., Eberhardt, M. S., Goldstein, D. E., Little, R. R., Wiedmeyer, H.-M., & Byrd-Holt, D. D. (1998) · Diabetes Care · doi:10.2337/diacare.21.4.518 · Cited by 2,703
Pathogenesis of NIDDM. A balanced overview.
DeFronzo, R. A., Bonadonna, R. C., & Ferrannini, E. (1992) · Diabetes Care · doi:10.2337/diacare.15.3.318 · Cited by 2,085
Amos, A. F., McCarty, D. J., & Zimmet, P. (1997) · Diabetic Medicine · doi:10.1002/(sici)1096-9136(199712)14:5+<s7::aid-dia522>3.0.co;2-r · Cited by 1,882
Pharmacologic Therapy for Type 2 Diabetes Mellitus
DeFronzo, R. A. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-4-199908170-00008 · Cited by 1,173
Asano, N., Nash, R. J., Molyneux, R. J., & Fleet, G. W. J. (2000) · Tetrahedron: Asymmetry · doi:10.1016/s0957-4166(00)00113-0 · Cited by 1,015
Carson, M. (1991) · Journal of Applied Crystallography · doi:10.1107/s0021889891007240 · Cited by 808
Magnusson, I., Rothman, D. L., Katz, L. D., Shulman, R. G., & Shulman, G. I. (1992) · Journal of Clinical Investigation · doi:10.1172/jci115997 · Cited by 757
Economic Consequences of Diabetes Mellitus in the U.S. in 1997
American Diabetes Association (1998) · Diabetes Care · doi:10.2337/diacare.21.2.296 · Cited by 652
Quantitation of Hepatic Glycogenolysis And Gluconeogenesis in Fasting Humans With 13 C NMR
Rothman, D. L., Magnusson, I., Katz, L. D., Shulman, R. G., & Shulman, G. I. (1991) · Science · doi:10.1126/science.1948033 · Cited by 546
Contributions of gluconeogenesis to glucose production in the fasted state
Landau, B. R., Wahren, J., Chandramouli, V, Schumann, W. C., Ekberg, K., & Kalhan, S. C. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118803 · Cited by 487
Implications of the United Kingdom Prospective Diabetes Study
American Diabetes Association (2003) · Diabetes Care · doi:10.2337/diacare.26.2007.s28 · Cited by 449
Specific features of glycogen metabolism in the liver
BOLLEN, M., KEPPENS, S., & STALMANS, W. (1998) · Biochemical Journal · doi:10.1042/bj3360019 · Cited by 409
The Family of Glycogen Phosphorylases: Structure and Functio
Newgard, C. B., Hwang, P. K., & Fletterick, R. J. (1989) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238909082552 · Cited by 397
Gastaldelli, A., Baldi, S., Pettiti, M., Toschi, E., Camastra, S., Natali, A., Landau, B. R., & Ferrannini, E. (2000) · Diabetes · doi:10.2337/diabetes.49.8.1367 · Cited by 320
Diabetes in America, 2nd edition
Harris, M. I. (1995) · Diabetes Research and Clinical Practice · doi:10.1016/0168-8227(95)90020-9 · Cited by 316
Ekberg, K., Landau, B. R., Wajngot, A., Chandramouli, V, Efendic, S., Brunengraber, H., & Wahren, J. (1999) · Diabetes · doi:10.2337/diabetes.48.2.292 · Cited by 287
Interleukin-6 gene polymorphism and insulin sensitivity.
Fernández-Real, J. M., Broch, M., Vendrell, J., Gutiérrez, C., Casamitjana, R., Pugeat, M., Richart, C., & Ricart, W. (2000) · Diabetes · doi:10.2337/diabetes.49.3.517 · Cited by 244
Discovery of a human liver glycogen phosphorylase inhibitor that lowers blood glucose in vivo
Martin, W. H., Hoover, D. J., Armento, S. J., Stock, I. A., McPherson, R. K., Danley, D. E., Stevenson, R. W., Barrett, E. J., & Treadway, J. L. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.4.1776 · Cited by 232
Self-citationRole of Liver in Pathophysiology of NIDDM
Consoli, A. (1992) · Diabetes Care · doi:10.2337/diacare.15.3.430 · Cited by 209
Hepatic gluconeogenic fluxes and glycogen turnover during fasting in humans. A stable isotope study.
Hellerstein, M. K., Neese, R. A., Linfoot, P., Christiansen, M., Turner, S., & Letscher, A. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119644 · Cited by 188
Psaty, B. M. (1999) · JAMA · doi:10.1001/jama.282.8.786 · Cited by 187
Hyperglycemic Crises in Patients With Diabetes Mellitus
Association, A. D. (2001) · Diabetes Care · doi:10.2337/diacare.24.1.154 · Cited by 174
The role of the liver in metabolic homeostasis: Implications for inborn errors of metabolism
van den Berghe, G. (1991) · Journal of Inherited Metabolic Disease · doi:10.1007/bf01797914 · Cited by 159
Perspective: The Insulin Signaling System--A Common Link in the Pathogenesis of Type 2 Diabetes
Withers, D. J., & White, M. F. (2000) · Endocrinology · doi:10.1210/endo.141.6.7584 · Cited by 141
A new allosteric site in glycogen phosphorylase b as a target for drug interactions
Oikonomakos, N. G., Skamnaki, V. T., Tsitsanou, K. E., Gavalas, N. G., & Johnson, L. N. (2000) · Structure · doi:10.1016/s0969-2126(00)00144-1 · Cited by 132
Human liver glycogen phosphorylase inhibitors bind at a new allosteric site
Rath, V. L., Ammirati, M. J., Danley, D. E., Ekstrom, J. L., Gibbs, E. M., Hynes, T. R., Mathiowetz, A. M., McPherson, R. K., Olson, T. V., Treadway, J. L., et al. (2000) · Chemistry & Biology · doi:10.1016/s1074-5521(00)00004-1 · Cited by 126
Self-citationFlavopiridol Inhibits Glycogen Phosphorylase by Binding at the Inhibitor Site
Oikonomakos, N. G., Schnier, J. B., Zographos, S. E., Skamnaki, V. T., Tsitsanou, K. E., & Johnson, L. N. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m004485200 · Cited by 124
Inhibition of glycogenolysis in primary rat hepatocytes by 1,4-dideoxy-1,4-imino-D-arabinitol
ANDERSEN, B., RASSOV, A., Westergaard, N., & Lundgren, K. (1999) · Biochemical Journal · doi:10.1042/bj3420545 · Cited by 122
King, L. M., & Opie, L. H. (1998) · Molecular and Cellular Biochemistry · doi:10.1023/a:1006870419309 · Cited by 122
Watson, K. A., Mitchell, E. P., Johnson, L. N., Bichard, C. J. F., Orchard, M. G., Fleet, G. W. J., Oikonomakos, N. G., Leonidas, D. D., & Son, J. C. (1994) · Biochemistry · doi:10.1021/bi00185a011 · Cited by 119
Synergistic regulation of phosphorylase a by glucose and caffeine.
Kasvinsky, P. J., Shechosky, S., & Fletterick, R. J. (1978) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)34291-6 · Cited by 117
Tayek, J. A., & Katz, J. J. (1996) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1996.270.4.e709 · Cited by 114
King, L. M., & Opie, L. H. (1998) · PubMed · Cited by 109
Glucose analog inhibitors of glycogen phosphorylase: the design of potential drugs for diabetes
Martin, J. L., Veluraja, K., Ross, K., Johnson, L. N., Fleet, G. W. J., Ramsden, N. G., Bruce, I., Orchard, M. G., & Oikonomakos, N. G. (1991) · Biochemistry · doi:10.1021/bi00106a006 · Cited by 108
Rath, V. L., Ammirati, M., LeMotte, P. K., Fennell, K. F., Mansour, M. N., Danley, D. E., Hynes, T. R., Schulte, G. K., Wasilko, D. J., & Pandit, J. (2000) · Molecular Cell · doi:10.1016/s1097-2765(05)00006-7 · Cited by 107
Indole-2-carboxamide Inhibitors of Human Liver Glycogen Phosphorylase
Hoover, D. J., Snow, S. L., Burgess‐Henry, J., Martin, W. H., Armento, S. J., Stock, I. A., McPherson, R. K., Genereux, P. E., Gibbs, E. M., & Treadway, J. L. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm980264k · Cited by 101
Self-citationArmstrong, C. G., DOHERTY, M. J., & Cohen, P. T. W. (1998) · Biochemical Journal · doi:10.1042/bj3360699 · Cited by 93
Fosgerau, K., Westergaard, N., Quistorff, B., Grunnet, N., Kristiansen, M., & Lundgren, K. (2000) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.2000.1930 · Cited by 91
Promoting Early Diagnosis and Treatment of Type 2 Diabetes: The National Diabetes Education Program
Clark, C. M., FRADKIN, J. E., Hiss, R. G., Lorenz, R. A., Vinicor, F., & Warren‐Boulton, E. (2000) · JAMA · doi:10.1001/jama.284.3.363 · Cited by 91
Sprang, S. R., Goldsmith, E. J., Fletterick, R. J., Withers, S. G., & Madsen, N. B. (1982) · Biochemistry · doi:10.1021/bi00264a038 · Cited by 83
Limitations of the Mass Isotopomer Distribution Analysis of Glucose to Study Gluconeogenesis
Previs, S. F., Fernandez, C. A., Yang, D., Soloviev, M. V., David, F., & Brunengraber, H. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.34.19806 · Cited by 82
Zographos, S. E., Oikonomakos, N. G., Tsitsanou, K. E., Leonidas, D. D., Chrysina, E. D., Skamnaki, V. T., Bischoff, H., Goldmann, S., Watson, K. A., & Johnson, L. N. (1997) · Structure · doi:10.1016/s0969-2126(97)00292-x · Cited by 77
Lim, S. C., Tai, E. S., Tan, B. Y., Chew, S. K., & Tan, C. (2000) · Diabetes Care · doi:10.2337/diacare.23.3.278 · Cited by 73
Sv, E. (1998) · PubMed · Cited by 67
Kopelman, P. G., & Hitman, G. A. (1998) · The Lancet · doi:10.1016/s0140-6736(98)90267-7 · Cited by 66
Demonstration of a Glycogen/Glucose 1-Phosphate Cycle in Hepatocytes from Fasted Rats
Massillon, D., Bollen, M., WULF, H. D., Overloop, K., Vanstapel, F. J. L. A., Hecke, P. V., & Stalmans, W. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.33.19351 · Cited by 59
The Relationship Between Cow’s Milk Exposure and Type 1 Diabetes
Gerstein, H. C., & VanderMeulen, J. (1996) · Diabetic Medicine · Cited by 53
A critical evaluation of mass isotopomer distribution analysis of gluconeogenesis in vivo
Previs, S. F., Cline, G. W., & Shulman, G. I. (1999) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1999.277.1.e154 · Cited by 52
Diraison, F., Large, V., Brunengraber, H., & Beylot, M. (1998) · Diabetologia · doi:10.1007/s001250050892 · Cited by 52
Bergans, N., Stalmans, W., Goldmann, S., & Vanstapel, F. J. L. A. (2000) · Diabetes · doi:10.2337/diabetes.49.9.1419 · Cited by 49
Reducing the burden of diabetes: managing cardiovascular disease
KEEN, H., Clark, C. M., & Laakso, M. (1999) · Diabetes/Metabolism Research and Reviews · doi:10.1002/(sici)1520-7560(199905/06)15:3<186::aid-dmrr30>3.0.co;2-5 · Cited by 43
Oikonomakos, N. G., Tsitsanou, K. E., Zographos, S. E., Skamnaki, V. T., Goldmann, S., & Bischoff, H. (1999) · Protein Science · doi:10.1110/ps.8.10.1930 · Cited by 43
Vaag, A. A. (1999) · PubMed · Cited by 41
Tappy, L. (1995) · PubMed · Cited by 39
Waagepetersen, H. S., Westergaard, N., & Schousboe, A. (2000) · Neurochemistry International · doi:10.1016/s0197-0186(99)00146-1 · Cited by 37
Pg, K., & Ga, H. (1998) · PubMed · Cited by 36
Glucose metabolism and the postprandial state
Lefèbvre, & Scheen (1999) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.1999.00003.x · Cited by 31
M Board, Bollen, M., Stalmans, W., Kim, Y., Fleet, G. W. J., & Johnson, L. N. (1995) · Biochemical Journal · doi:10.1042/bj3110845 · Cited by 31
Glycemic control and cardiovascular disease in Type 2 diabetes: a review
Wild, S. H., Dunn, C. J., McKeigue, P., & Comte, S. (1999) · Diabetes/Metabolism Research and Reviews · Cited by 26
Limitations of the Mass Isotopomer Distribution Analysis of Glucose to Study Gluconeogenesis
Previs, S. F., Hallowell, P. T., Neimanis, K. D., David, F., & Brunengraber, H. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.27.16853 · Cited by 26
Inhibition of glycogenolysis enhances gluconeogenic precursor uptake by the liver of conscious dogs
Shiota, M., Jackson, P. A., Bischoff, H., McCaleb, M. L., Scott, M. F., Monohan, M., Neal, D. W., & Cherrington, A. D. (1997) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1997.273.5.e868 · Cited by 24
2 Hepatic glucose metabolism and insulin resistance in NIDDM and obesity
Barrett, E. J., & Liu, Z. (1993) · Baillière s Clinical Endocrinology and Metabolism · doi:10.1016/s0950-351x(05)80238-1 · Cited by 23
The Effect of Glycemic Control on the Incidence of Macrovascular Complications of Type 2 Diabetes
Stern, M. P. (1998) · Archives of Family Medicine · doi:10.1001/archfami.7.2.155 · Cited by 21
Measurement of gluconeogenesis and mass isotopomer analysis based on [U-13C]glucose
Radziuk, J., & Lee, W.-N. P. (1999) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1999.277.2.e199 · Cited by 20
Glycogen: its mode of formation and contribution to hepatic glucose output in postabsorptive humans
Pimenta, W. P., Nurjhan, N., Jansson, P., Stümvoll, M., Gerich, J. E., & Korytkowski, M. T. (1994) · Diabetologia · doi:10.1007/bf00417694 · Cited by 19
FDA approach to the regulation of drugs for diabetes
Fleming, A. (1999) · American Heart Journal · doi:10.1016/s0002-8703(99)70033-5 · Cited by 12
Uric acid inhibits liver phosphorylaseaactivity under simulated in vivo conditions
Ercan-Fang, N. G., Nuttall, F. Q., & Gannon, M. C. (2001) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2001.280.2.e248 · Cited by 8
The role of splanchnic glucose appearance in determining carbohydrate tolerance.
Rizza, R. A. (1996) · PubMed · Cited by 5
Bloch, G., & Velho, G. (1997) · PubMed · Cited by 2
Cited by
New drug targets for type 2 diabetes and the metabolic syndrome
Moller, D. E. (2001) · Nature · doi:10.1038/414821a · Cited by 1,008
Molecular Mechanisms and Clinical Implications of Reversible Protein S -Glutathionylation
Mieyal, J. J., Gallogly, M. M., Qanungo, S., Sabens, E. A., & Shelton, M. D. (2008) · Antioxidants & Redox Signaling · doi:10.1089/ars.2008.2089 · Cited by 523
Glucokinase and molecular aspects of liver glycogen metabolism
Agius, L. (2008) · Biochemical Journal · doi:10.1042/bj20080595 · Cited by 384
Targeting hepatic glucose metabolism in the treatment of type 2 diabetes
Rines, A. K., Sharabi, K., Tavares, C. D. J., & Puigserver, P. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.151 · Cited by 375
Ayeleso, T., Matumba, M., & Mukwevho, E. (2017) · Molecules · doi:10.3390/molecules22111915 · Cited by 333
Metadata
- Authors
- Treadway, J. L., Mendys, P., & Hoover, D. J.
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa Healthcare
- Published
- 2001-03
- Volume
- 10
- Issue
- 3
- Pages
- 439-454
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2154368316
- Cited by
- 260
- References
- 71
- FWCI
- 7.47
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.